BioCentury | Aug 13, 2007
Finance

Ebb & Flow

...he founded. Before that, he was a portfolio manager and head of healthcare research at Duquesne Capital...
BioCentury | Jul 16, 2007
Company News

Agensys board of directors update

...Hironori Hozoji, investment officer at JAFCO Life Science Investment; and Kenan Turnacioglu, managing director at Duquesne Capital...
BioCentury | May 1, 2006
Strategy

Big enough to share

...a mix of hedge funds, mutual funds and Astellas: Adage Capital; Apothecary; Brookside; Corriente Biotechnology; Duquesne Capital...
BioCentury | Apr 10, 2006
Finance

Ebb & Flow

...19.4%); TPG (12.5%); Morgenthaler (10.5%); OZ Master Fund (7.9%); Perseus-Soros Biopharmaceutical Fund (6.8%); Sequel (6.5%); Duquesne Capital...
BioCentury | Feb 21, 2005
Finance

Ebb & Flow

...or early 2007. Investors in the F round were Adage Capital; Apothecary; Brookside; Corriente Biotechnology; Duquesne Capital...
BioCentury | Feb 16, 2005
Financial News

FibroGen raises $100 million

...raised $100 million in a series F round through Adage Capital; Apothecary; Brookside; Corriente Biotechnology; Duquesne Capital...
BioCentury | Jan 19, 2004
Finance

Ebb & Flow

...raised to more than $180 million. Investors included Caxton Group; Gollust Management; Mountain Trail Investments; Duquesne Capital...
BioCentury | Jan 14, 2004
Financial News

Synta raises $50 million

...million in a series C round. Investors included Caxton Group; Gollust Management; Mountain Trail Investments; Duquesne Capital...
Items per page:
1 - 8 of 8
BioCentury | Aug 13, 2007
Finance

Ebb & Flow

...he founded. Before that, he was a portfolio manager and head of healthcare research at Duquesne Capital...
BioCentury | Jul 16, 2007
Company News

Agensys board of directors update

...Hironori Hozoji, investment officer at JAFCO Life Science Investment; and Kenan Turnacioglu, managing director at Duquesne Capital...
BioCentury | May 1, 2006
Strategy

Big enough to share

...a mix of hedge funds, mutual funds and Astellas: Adage Capital; Apothecary; Brookside; Corriente Biotechnology; Duquesne Capital...
BioCentury | Apr 10, 2006
Finance

Ebb & Flow

...19.4%); TPG (12.5%); Morgenthaler (10.5%); OZ Master Fund (7.9%); Perseus-Soros Biopharmaceutical Fund (6.8%); Sequel (6.5%); Duquesne Capital...
BioCentury | Feb 21, 2005
Finance

Ebb & Flow

...or early 2007. Investors in the F round were Adage Capital; Apothecary; Brookside; Corriente Biotechnology; Duquesne Capital...
BioCentury | Feb 16, 2005
Financial News

FibroGen raises $100 million

...raised $100 million in a series F round through Adage Capital; Apothecary; Brookside; Corriente Biotechnology; Duquesne Capital...
BioCentury | Jan 19, 2004
Finance

Ebb & Flow

...raised to more than $180 million. Investors included Caxton Group; Gollust Management; Mountain Trail Investments; Duquesne Capital...
BioCentury | Jan 14, 2004
Financial News

Synta raises $50 million

...million in a series C round. Investors included Caxton Group; Gollust Management; Mountain Trail Investments; Duquesne Capital...
Items per page:
1 - 8 of 8